Abstract: Systems, methods, and software to identify events of interest associated with an objects movement in an environment. In at least one implementation, a management service obtains video data from a plurality of cameras for the environment. The management service further obtains an identifier associated with a person from a sensor and identifies attributes associated with the person based on the identifier. Once the person is identified, the management service can track the movement of the person in the environment prior to arriving at the sensor using the video data and can identify items of interest for a summary based on the movement of the person in the environment and the attributes associated with the person.

Abstract: A security service can determine a synthetic context based at least in part on context data associated with a first malware sample, and detonate the first malware sample in the synthetic context to provide one or more first event records representing events performed by the first malware sample and detected during detonation. Additionally or alternatively, the security service can detonate the first malware sample and locate a second malware sample in a corpus based at least in part on the one or more first event records. Additionally or alternatively, the security service can receive event records representing events detected during a detonation of a first malware sample, the detonation based at least in part on context data, and locate a second malware sample in the corpus based at least in part on the one or more reference event records.

Abstract: A security service can determine a synthetic context based at least in part on context data associated with a first malware sample, and detonate the first malware sample in the synthetic context to provide one or more first event records representing events performed by the first malware sample and detected during detonation. Additionally or alternatively, the security service can detonate the first malware sample and locate a second malware sample in a corpus based at least in part on the one or more first event records. Additionally or alternatively, the security service can receive event records representing events detected during a detonation of a first malware sample, the detonation based at least in part on context data, and locate a second malware sample in the corpus based at least in part on the one or more reference event records.

Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.

Abstract: This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein, derivatives, or compounds disclosed herein optionally substituted with one or more substitutes including optional salt and prodrug forms. In certain embodiments, this disclosure relates to sulfonylurea compounds and uses reported herein.

Abstract: A security service can determine a synthetic context based at least in part on context data associated with a first malware sample, and detonate the first malware sample in the synthetic context to provide one or more first event records representing events performed by the first malware sample and detected during detonation. Additionally or alternatively, the security service can detonate the first malware sample and locate a second malware sample in a corpus based at least in part on the one or more first event records. Additionally or alternatively, the security service can receive event records representing events detected during a detonation of a first malware sample, the detonation based at least in part on context data, and locate a second malware sample in the corpus based at least in part on the one or more reference event records.

Abstract: A system and method are disclosed in which a node of a peer-to-peer (P2P) network supporting a blockchain is able to restart following network or power disruption (or is able to initially join the blockchain network) by bootstrapping information from one or more peer nodes in the P2P network. The bootstrapping operation involves communication between the Trusted Execution Environments (TEEs) of the two or more nodes. The system and method ensure that the retrieval of data related to the blockchain state are not from untrusted parts of the peer node(s) and the data has not been tampered with (avoidance of replay attacks).

Abstract: This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein, derivatives, or compounds disclosed herein optionally substituted with one or more substitutes including optional salt and prodrug forms. In certain embodiments, this disclosure relates to sulfonylurea compounds and uses reported herein.

Abstract: A method of treating leukaemia comprising orally administering to a patient in need thereof reduced daily doses of nilotinib of 100 mg to 600 mg, wherein the nilotinib is administered in a dosage form having a composition comprising nilotinib butanedisulphonate (2:1) or nilotinib butanedisulphonate (1:1).

Abstract: Systems and methods according to various embodiments disclose a worker process manager adapted to spawn one or more worker processes on a server and to load an application on each of the worker processes. The worker process manager is adapted to isolate the one or more worker processes from each other and to control resource usage by the worker processes. A resource manager is adapted to detect applications that overuse system resources. The worker process manager is adapted to isolate worker processes and to control resource usage using one or more of the following techniques: least-privilege execution, messaging isolation, credentials isolation, data isolation, network isolation, fair share resource usage, and managed runtime security. Heuristic algorithms are used to detect applications that frequently overuse system resources that are unchargeable and that cause system unresponsiveness.

Abstract: A system and method are disclosed in which a node of a peer-to-peer (P2P) network supporting a blockchain is able to restart following network or power disruption (or is able to initially join the blockchain network) by bootstrapping information from one or more peer nodes in the P2P network. The bootstrapping operation involves communication between the Trusted Execution Environments (TEEs) of the two or more nodes. The system and method ensure that the retrieval of data related to the blockchain state are not from untrusted parts of the peer node(s) and the data has not been tampered with (avoidance of replay attacks).

Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.

Abstract: The present invention relates to pharmaceutical compositions comprising dimethyl fumarate and a pharmaceutically acceptable agent which inhibits the enzyme catalyzed degradation of dimethyl fumarate.

Abstract: The present invention relates to pharmaceutical compositions comprising dimethyl fumarate and a pharmaceutically acceptable agent which inhibits the enzyme catalyzed degradation of dimethyl fumarate.

Abstract: Pharmaceutical compositions comprising ceftibuten or a pharmaceutically acceptable salt thereof, and clavulanic acid or a pharmaceutically acceptable salt thereof are disclosed.

Abstract: The invention discloses a glass lined metal micro-reactor with enhanced heat transfer efficiency in continuous flow operation. More particularly, the invention discloses a glass lined micro-reactor that can be reassembled. The invention provides a novel glass lined metal micro-reactor with micro fluidic channels that provide a better mixing, better heat exchange, and better temperature control. The micro fluidic channels machined in the glass lined metal reactor/mixer may be straight, curved, lamellar, flower shaped, or spiral such that the cross sectional area of the micro fluidic channel is configured to suit the cross sectional area of the micro-reactor.

Abstract: In an embodiment, a method includes registering applications and network services for notification of an out-of-band introduction, and using the out-of-band introduction to bootstrap secure in-band provisioning of credentials and policies that are used to control subsequent access and resource sharing on an in-band channel. In another embodiment, an apparatus implements the method.

Abstract: The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.

Abstract: A compact sustained release tablet comprising divalproex or its pharmaceutically acceptable salts as a sole active ingredient is present in an amount equivalent to from about 700 mg to about 1500 mg of valproic acid and pharmaceutically acceptable tablet excipients; wherein weight ratio of pharmaceutically acceptable tablet excipients to divalproex and/or its salt is less than 1, the tablet is suitable for once a day administration and when orally administered, with or without food, the ratio of mean AUC0_inf-fasted to mean AUC0_inf-fed is within the range of 0.9 to 1.1.

Abstract: Pharmaceutical compositions comprising ceftibuten or a pharmaceutically acceptable derivative thereof, and clavulanic acid or a pharmaceutically acceptable derivative thereof are disclosed.